Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
David Schaffer
AddedMar 31, 2024
UpdatedMay 31, 2026
David Schaffer

David Schaffer

Co-Founder, 4D Molecular Therapeutics

CrunchbaseLinkedIn

David Schaffer's Career

4D Molecular Therapeutics
4D Molecular Therapeutics

Emeryville, CA, US

Co-Founder
Axent Biosciences
Axent Biosciences

Berkeley, CA, US

Co-Founder
Valitor
Valitor

Berkeley, CA, US

Board Member· Board
GenEdit
GenEdit

South San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

David Schaffer's Career

4D Molecular Therapeutics
4D Molecular Therapeutics
Public$295M1402013Emeryville, CA, US
Co-Founder

Leadership at 4D Molecular Therapeutics

David KirnDavid KirnBoard Member
Theresa JankeTheresa JankeCo-Founder
Charles TheuerCharles TheuerBoard Member
Jacob ChackoJacob ChackoBoard Member
Shawn TomaselloShawn TomaselloBoard Member
John F. MilliganJohn F. MilliganBoard Member

Similar to 4D Molecular Therapeutics

Apertura Gene TherapyApertura Gene TherapyNew York City, NY, USGene Therapyest. 2021Apertura Gene TherapyNew York City, NY, US · est. 2021

Apertura Gene Therapy: A biotech firm pioneering gene therapy for debilitating diseases.

Series A · $67M29
C4 TherapeuticsC4 TherapeuticsCambridge, MA, USCancer Therapiesest. 2015C4 TherapeuticsCambridge, MA, US · est. 2015

C4 Therapeutics, a US biotech firm, innovates early-stage therapies to treat cancer and neurological diseases.

Public · $298.8M146
Intergalactic TherapeuticsIntergalactic TherapeuticsCambridge, MA, USGene Therapyest. 2020Intergalactic TherapeuticsCambridge, MA, US · est. 2020

Intergalactic Therapeutics: Pioneering the future of non-viral gene therapy for patients.

Series A · $75M41
Solid BiosciencesSolid BiosciencesCambridge, MA, USGene Therapy, Therapiesest. 2013Solid BiosciencesCambridge, MA, US · est. 2013

Solid Biosciences Inc., a US-based biotech firm, develops therapies and devices for muscular dystrophy.

Public · $441.3M87
Axent Biosciences
Axent Biosciences
Pre-Seed$100k122016Berkeley, CA, US
Co-Founder

Leadership at Axent Biosciences

Hunter JohnsonHunter JohnsonCo-Founder
Riya MuckomRiya MuckomCo-Founder
Valitor
Valitor
Series B$39M162010Berkeley, CA, US
Board Member· Board

Leadership at Valitor

Gail MaderisGail MaderisBoard Member
Steven LoSteven LoCEO
Walter H. MoosWalter H. MoosBoard Member
GenEdit
GenEdit
Series A$67.7M472016South San Francisco, CA, US
Board Member· Board

Leadership at GenEdit

Kunwoo LeeKunwoo LeeBoard Member
Hyo Min ParkHyo Min ParkCo-Founder
June LeeJune LeeBoard Member
Niren MurthyNiren MurthyCo-Founder
Jiwoong ChunJiwoong ChunBoard Member

Similar to GenEdit

Editas MedicineEditas MedicineCambridge, MA, USGene Editing, Therapiesest. 2013Editas MedicineCambridge, MA, US · est. 2013

Editas Medicine, Inc.: A clinical-stage biotech firm pioneering CRISPR-based therapies for rare diseases.

Public · $931.6M226
SynthegoSynthegoRedwood City, CA, USCrispr Kits, Gene Editingest. 2012SynthegoRedwood City, CA, US · est. 2012

US-based Synthego Corp. provides software solutions for biological research, primarily serving California.

Series E · $460.5M322
Mammoth BiosciencesMammoth BiosciencesSan Francisco, CA, USCrispr Productsest. 2017Mammoth BiosciencesSan Francisco, CA, US · est. 2017

Mammoth Biosciences: An American biotech firm innovating CRISPR products to improve lives.

Series D · $264.5M195
Intellia TherapeuticsIntellia TherapeuticsCambridge, MA, USGene Editing, Therapiesest. 2014Intellia TherapeuticsCambridge, MA, US · est. 2014

Cambridge-based Intellia Therapeutics pioneers gene editing therapies for genetic diseases.

Public · $1.2B598

David Schaffer's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to David Schaffer

David KurtzDavid KurtzCo-Founder · Foresight DiagnosticsShrikant PawarShrikant PawarCo-Founder · ChestAiJeffery GreenblattJeffery GreenblattFounder & CEO · Emerging FuturesDavid A. WeitzDavid A. WeitzCo-Founder · CapsumDavid YoffieDavid YoffieBoard Member · Commonwealth Financial NetworkDavid EricksonDavid EricksonBoard Member · VitaScan